Announcement of change of the spokesperson

Announcement of change of Chairman of the Board

Announcement of death of Chairman of the Board (Supplementary Statement on the circumstances of his deputy)

Announcement of change of director

Announcement of death of Chairman of the Board

OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By USPTO

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP505, to US FDA

Announcement on behalf of AP Biosciences that it obtains the Internal Control Special Audit Report by CPA

Amendments to related matters that OBI forfeits part of subscription rights of Obigen’s cash capital increase and distributes the rights to its shareholders

OBI sets target date of distribution of other benefits from forfeiture of subscription rights to its shareholders for Obigen’s 2022 cash capital increase